Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

362
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
362
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

1.0K
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
1.0K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

154
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
154
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

992
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
992
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

597
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
597
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

487
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
487

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease.

World journal of gastroenterology·2026
Same author

Pharmacokinetic Modeling of Ticagrelor and Ticagrelor Active Metabolite Removal by the DrugSorb-ATR Device in a Randomized Controlled Study of Patients Undergoing Cardiac Surgery.

Journal of cardiovascular pharmacology·2026
Same author

Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.

Clinical pharmacokinetics·2025
Same author

Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP-8121).

Clinical and translational science·2025

Related Experiment Video

Updated: Apr 27, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Dashboard systems: implementing pharmacometrics from bench to bedside.

Diane R Mould1, Richard N Upton, Jessica Wojciechowski

  • 1Projections Research Inc, 535 Springview Lane, Phoenixville, Pennsylvania, 19460, USA, drmould@attglobal.net.

The AAPS Journal
|June 21, 2014
PubMed
Summary
This summary is machine-generated.

Dashboard systems offer integrated clinical decision support to improve patient outcomes and reduce costs. Their application in model-based drug development (MBDD) streamlines processes and expedites timely updates.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Related Experiment Videos

Last Updated: Apr 27, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Area of Science:

  • Health Informatics
  • Computational Pharmacology
  • Clinical Decision Support Systems

Background:

  • Increasing interest in medical decision-support tools, particularly dashboard systems, for clinical environments.
  • High healthcare costs necessitate tools for improving patient outcomes, clinical efficiency, and cost containment.
  • Rising drug development costs highlight the need for streamlined processes like model-based drug development (MBDD).

Purpose of the Study:

  • To present background information on dashboard systems.
  • To propose the application of dashboard systems in both clinical practice and drug development.
  • To explore how dashboard systems can enhance efficiency and cost-effectiveness in healthcare and drug development.

Main Methods:

  • Review of existing literature on dashboard systems and their functionalities.
  • Conceptual proposal for integrating dashboard systems into clinical decision-making.
  • Discussion on the adaptation of dashboard systems for model-based drug development (MBDD).

Main Results:

  • Dashboard systems integrate diverse therapeutic information and calculations into a single clinical interface.
  • MBDD implementation challenges, including resource demands for timely updates, can be mitigated by dashboard systems.
  • Dashboard systems can expedite model updates with new data, ensuring timely availability of modeling results.

Conclusions:

  • Dashboard systems hold significant potential to improve patient outcomes, clinical efficiency, and healthcare cost containment.
  • The application of dashboard systems in drug development can reduce resource requirements and accelerate the MBDD process.
  • Dashboard systems represent a valuable tool for both clinical decision support and streamlining drug development.